(Q35556109)

8 August 2017

1 reference

title

Interferon-beta in the treatment of relapsing-remitting multiple sclerosis (English)

1 reference

8 August 2017

Interferon-β in the treatment of relapsing–remitting multiple sclerosis (English)

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

20 March 2024

author name string

Michel Revel

1

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14550504

20 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0163725803000858?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

https://api.elsevier.com/content/article/PII:S0163725803000858?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

Pharmacology & Therapeutics

20 March 2024

published in

1 reference

8 August 2017

volume

100

1 reference

8 August 2017

issue

1

1 reference

8 August 2017

page(s)

49-62

1 reference

Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Failure of copolymer I to inhibit the human T-cell response to myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Interferon-? therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

1 reference

7 January 2021

Genetic analysis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Multiple sclerosis and viruses: An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Mechanisms of immunomodulation by glatiramer acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Multiple sclerosis: infectious hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Intrathecal interferon in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

1 reference

7 January 2021

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Site-specific mutagenesis of the human fibroblast interferon gene

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Treat early, but treat hard: Interferon-beta dose makes a difference

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Diagnostic criteria for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Epidemiology of multiple sclerosis: a critical overview.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Intramuscular human interferon-beta injections in treatment of condylomata acuminata

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Physiological approaches to neuroprotection. boosting of protective autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

The cost of delaying treatment in multiple sclerosis: what is lost is not regained

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Multiple sclerosis: nature or nurture?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Axonal pathology in multiple sclerosis: relationship to neurologic disability

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

The natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2803%2900085-8

7 January 2021

Clinical infections and multiple sclerosis: contribution from analytical epidemiology

7

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

A reassessment of the distribution of multiple sclerosis

20 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

An in vivo and post mortem MRI study in multiple sclerosis with pathological correlation

20 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

20 March 2024

62

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients

20 March 2024

66

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

Contrast enhancement and the acute lesion in multiple sclerosis

20 March 2024

69

1 reference

https://api.crossref.org/works/10.1016/S0163-7258(03)00085-8

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference